ConductScience.org, home

Paper26229727

Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Coyne CP and 4 others. J Cancer Ther, 2011. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. Papers, record 26229727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26229727

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.
PubMed
Journal
J Cancer Ther
PubMed
Year
2011
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.46
iCite
Revised in PubMed
2020-09-29
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coyne CPCody P
2Jones TToni
3Sygula AAndrzej
4Bailey JJohn
5Pinchuk LLesya

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
T35 OD010432NIH HHSUnited StatesT35OD010432PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References88

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115458769The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?Pharmacol Res2004https://conductscience.org/library/papers/15458769PubMed
219101136In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance.Biosens Bioelectron2009https://conductscience.org/library/papers/19101136PubMed
312459020
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
J Med Chem2002https://conductscience.org/library/papers/12459020PubMed
417131338The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.Int J Cancer2007https://conductscience.org/library/papers/17131338PubMed
58564396Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro.Bioorg Med Chem1995https://conductscience.org/library/papers/8564396PubMed
617702197Anthracycline-based combined chemotherapy in the mouse model.Eur J Drug Metab Pharmacokinet2007https://conductscience.org/library/papers/17702197PubMed
72515870Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.Mol Biother1989https://conductscience.org/library/papers/2515870PubMed
815073137Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.Clin Cancer Res2004https://conductscience.org/library/papers/15073137PubMed
915621674Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation.J Drug Target2004https://conductscience.org/library/papers/15621674PubMed
108327892Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.Science1993https://conductscience.org/library/papers/8327892PubMed
1110589780Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.Clin Cancer Res1999https://conductscience.org/library/papers/10589780PubMed
1211821453Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol2002https://conductscience.org/library/papers/11821453PubMed
1319253922Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.Chembiochem2009https://conductscience.org/library/papers/19253922PubMed
1410632061Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution.Bioorg Med Chem1999https://conductscience.org/library/papers/10632061PubMed
1515567293A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate.Eur J Pharm Sci2004https://conductscience.org/library/papers/15567293PubMed
1616611663Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.Jpn J Clin Oncol2006https://conductscience.org/library/papers/16611663PubMed
171382845Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.Cancer Res1992https://conductscience.org/library/papers/1382845PubMed
1815382077Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.Int J Cancer2004https://conductscience.org/library/papers/15382077PubMed
199870393Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis.Electrophoresis1998https://conductscience.org/library/papers/9870393PubMed
2010928049Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.Anticancer Res2000https://conductscience.org/library/papers/10928049PubMed

See all 88 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
27574398Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).Drug Des Devel Ther2016https://conductscience.org/library/papers/27574398PubMed
27561602Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).Chem Biol Drug Des2017https://conductscience.org/library/papers/27561602PubMed
26613088Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).J Pharm Drug Deliv Res2015https://conductscience.org/library/papers/26613088PubMed
26251840Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.J Clin Exp Oncol2013https://conductscience.org/library/papers/26251840PubMed
26225219Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).Med Chem (Los Angeles)2013https://conductscience.org/library/papers/26225219PubMed
26225216
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.
J Cancer Ther2012https://conductscience.org/library/papers/26225216PubMed
26225190
Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.
Cancer Clin Oncol2012https://conductscience.org/library/papers/26225190PubMed
25844392
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.
J Cancer Res Ther Oncol2014https://conductscience.org/library/papers/25844392PubMed
25821636Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.J Cancer Ther2015https://conductscience.org/library/papers/25821636PubMed
22191802Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.Cancer Biother Radiopharm2012https://conductscience.org/library/papers/22191802PubMed

Download CSV of cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
BBC327113PubTator's text mininghttps://conductscience.org/library/genes/27113NCBI Gene
BCL2L1110018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
CASP8841PubTator's text mininghttps://conductscience.org/library/genes/841NCBI Gene
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
CAT847PubTator's text mininghttps://conductscience.org/library/genes/847NCBI Gene
CD74972PubTator's text mininghttps://conductscience.org/library/genes/972NCBI Gene
DDIT31649PubTator's text mininghttps://conductscience.org/library/genes/1649NCBI Gene
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF3A8661PubTator's text mininghttps://conductscience.org/library/genes/8661NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FADD8772PubTator's text mininghttps://conductscience.org/library/genes/8772NCBI Gene
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene
FOXO32309PubTator's text mininghttps://conductscience.org/library/genes/2309NCBI Gene
GSK3B2932PubTator's text mininghttps://conductscience.org/library/genes/2932NCBI Gene
PRDX525824PubTator's text mininghttps://conductscience.org/library/genes/25824NCBI Gene
TOP2A7153PubTator's text mininghttps://conductscience.org/library/genes/7153NCBI Gene

See all 22 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26229727

GET https://conductscience.org/api/papers/v1/26229727/references?page=2